BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 23435034)

  • 1. Breast cancer susceptibility associated with rs1219648 (fibroblast growth factor receptor 2) and postmenopausal hormone therapy use in a population-based United States study.
    Andersen SW; Trentham-Dietz A; Figueroa JD; Titus LJ; Cai Q; Long J; Hampton JM; Egan KM; Newcomb PA
    Menopause; 2013 Mar; 20(3):354-8. PubMed ID: 23435034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Variation in the FGFR2 gene and the effects of postmenopausal hormone therapy on invasive breast cancer.
    Prentice RL; Huang Y; Hinds DA; Peters U; Pettinger M; Cox DR; Beilharz E; Chlebowski RT; Rossouw JE; Caan B; Ballinger DG
    Cancer Epidemiol Biomarkers Prev; 2009 Nov; 18(11):3079-85. PubMed ID: 19861516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymorphisms in the BRCA1 and ABCB1 genes modulate menopausal hormone therapy associated breast cancer risk in postmenopausal women.
    MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk
    Breast Cancer Res Treat; 2010 Apr; 120(3):727-36. PubMed ID: 19672706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A study on genetic variants of Fibroblast growth factor receptor 2 (FGFR2) and the risk of breast cancer from North India.
    Siddiqui S; Chattopadhyay S; Akhtar MS; Najm MZ; Deo SV; Shukla NK; Husain SA
    PLoS One; 2014; 9(10):e110426. PubMed ID: 25333473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer.
    Hunter DJ; Kraft P; Jacobs KB; Cox DG; Yeager M; Hankinson SE; Wacholder S; Wang Z; Welch R; Hutchinson A; Wang J; Yu K; Chatterjee N; Orr N; Willett WC; Colditz GA; Ziegler RG; Berg CD; Buys SS; McCarty CA; Feigelson HS; Calle EE; Thun MJ; Hayes RB; Tucker M; Gerhard DS; Fraumeni JF; Hoover RN; Thomas G; Chanock SJ
    Nat Genet; 2007 Jul; 39(7):870-4. PubMed ID: 17529973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single nucleotide polymorphisms associated with risk for contralateral breast cancer in the Women's Environment, Cancer, and Radiation Epidemiology (WECARE) Study.
    Teraoka SN; Bernstein JL; Reiner AS; Haile RW; Bernstein L; Lynch CF; Malone KE; Stovall M; Capanu M; Liang X; Smith SA; Mychaleckyj J; Hou X; Mellemkjaer L; Boice JD; Siniard A; Duggan D; Thomas DC; ; Concannon P
    Breast Cancer Res; 2011; 13(6):R114. PubMed ID: 22087758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-penetrance susceptibility variants and postmenopausal oestrogen receptor positive breast cancer.
    Özgöz A; İçduygu FM; Yükseltürk A; ŞamlI H; Öztürk KH; Başkan Z
    J Genet; 2020; 99():. PubMed ID: 32366738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of aggressive breast cancer in women of Han nationality carrying TGFB1 rs1982073 C allele and FGFR2 rs1219648 G allele in North China.
    Chen XH; Li XQ; Chen Y; Feng YM
    Breast Cancer Res Treat; 2011 Jan; 125(2):575-82. PubMed ID: 20640597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hormone-dependent effects of FGFR2 and MAP3K1 in breast cancer susceptibility in a population-based sample of post-menopausal African-American and European-American women.
    Rebbeck TR; DeMichele A; Tran TV; Panossian S; Bunin GR; Troxel AB; Strom BL
    Carcinogenesis; 2009 Feb; 30(2):269-74. PubMed ID: 19028704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of polymorphisms in intron 2 of FGFR2 and breast cancer risk in Сhinese women.
    Pan Z; Bao Y; Zheng X; Cao W; Cheng W; Xu X
    Tsitol Genet; 2016; 50(5):59-64. PubMed ID: 30480917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FGFR2 intronic SNPs and breast cancer risk: associations with tumor characteristics and interactions with exogenous exposures and other known breast cancer risk factors.
    Marian C; Ochs-Balcom HM; Nie J; Kallakury BV; Ambrosone CB; Trevisan M; Edge S; Shields PG; Freudenheim JL
    Int J Cancer; 2011 Aug; 129(3):702-12. PubMed ID: 20853316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic polymorphisms in phase I and phase II enzymes and breast cancer risk associated with menopausal hormone therapy in postmenopausal women.
    MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk
    Breast Cancer Res Treat; 2010 Jan; 119(2):463-74. PubMed ID: 19424794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic variants in fibroblast growth factor receptor 2 (FGFR2) contribute to susceptibility of breast cancer in Chinese women.
    Liang J; Chen P; Hu Z; Zhou X; Chen L; Li M; Wang Y; Tang J; Wang H; Shen H
    Carcinogenesis; 2008 Dec; 29(12):2341-6. PubMed ID: 18845558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genome-Wide Association Studies (GWAS) breast cancer susceptibility loci in Arabs: susceptibility and prognostic implications in Tunisians.
    Shan J; Mahfoudh W; Dsouza SP; Hassen E; Bouaouina N; Abdelhak S; Benhadjayed A; Memmi H; Mathew RA; Aigha II; Gabbouj S; Remadi Y; Chouchane L
    Breast Cancer Res Treat; 2012 Oct; 135(3):715-24. PubMed ID: 22910930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A genome-wide association study to identify genetic susceptibility loci that modify ductal and lobular postmenopausal breast cancer risk associated with menopausal hormone therapy use: a two-stage design with replication.
    Hein R; Flesch-Janys D; Dahmen N; Beckmann L; Lindström S; Schoof N; Czene K; Mittelstraß K; Illig T; Seibold P; Behrens S; Humphreys K; Li J; Liu J; Olson JE; Wang X; Hankinson SE; Truong T; Menegaux F; Dos Santos Silva I; Johnson N; ; Chen ST; Yu JC; Ziogas A; Kataja V; Kosma VM; Mannermaa A; Anton-Culver H; Shen CY; Brauch H; Peto J; Guénel P; Kraft P; Couch FJ; Easton DF; Hall P; Chang-Claude J
    Breast Cancer Res Treat; 2013 Apr; 138(2):529-542. PubMed ID: 23423446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers.
    Eisen A; Lubinski J; Gronwald J; Moller P; Lynch HT; Klijn J; Kim-Sing C; Neuhausen SL; Gilbert L; Ghadirian P; Manoukian S; Rennert G; Friedman E; Isaacs C; Rosen E; Rosen B; Daly M; Sun P; Narod SA;
    J Natl Cancer Inst; 2008 Oct; 100(19):1361-7. PubMed ID: 18812548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic variants in FGFR2 and TNRC9 genes are associated with breast cancer risk in Pakistani women.
    Mazhar A; Jamil F; Bashir Q; Ahmad MS; Masood M; Tanvir I; Rashid N; Waheed A; Afzal MN; Tariq MA
    Mol Med Rep; 2016 Oct; 14(4):3443-51. PubMed ID: 27572905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. +331G/A variant in the progesterone receptor gene, postmenopausal hormone use and risk of breast cancer.
    Kotsopoulos J; Tworoger SS; De Vivo I; Hankinson SE; Hunter DJ; Willett WC; Chen WY
    Int J Cancer; 2009 Oct; 125(7):1685-91. PubMed ID: 19462450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current evidence on the relationship between three polymorphisms in the FGFR2 gene and breast cancer risk: a meta-analysis.
    Zhang J; Qiu LX; Wang ZH; Leaw SJ; Wang BY; Wang JL; Cao ZG; Gao JL; Hu XC
    Breast Cancer Res Treat; 2010 Nov; 124(2):419-24. PubMed ID: 20300826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variation in the FGFR2 gene and the effect of a low-fat dietary pattern on invasive breast cancer.
    Prentice RL; Huang Y; Hinds DA; Peters U; Cox DR; Beilharz E; Chlebowski RT; Rossouw JE; Caan B; Ballinger DG
    Cancer Epidemiol Biomarkers Prev; 2010 Jan; 19(1):74-9. PubMed ID: 20056625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.